We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+36.17%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$622M
AUM Growth
+$149M
Cap. Flow
+$50.8M
Cap. Flow %
8.17%
Top 10 Hldgs %
69.69%
Holding
34
New
10
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$19M
2
THRD
Third Harmonic Bio
THRD
+$18.4M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.6M
4
AKRO
Akero Therapeutics
AKRO
+$11.4M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.9M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.2M
2
KURA icon
Kura Oncology
KURA
+$14.3M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$11.5M
4
COGT icon
Cogent Biosciences
COGT
+$8.56M
5
TNYA icon
Tenaya Therapeutics
TNYA
+$2.01M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
2 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
26
DELISTED
Esperion Therapeutics
ESPR
$3.13M 0.5%
+467,468
New +$3.21M
IMUX icon
27
Immunic
IMUX
$182M
$2.82M 0.45%
89,301
– –
BLSA
28
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.5M 0.4%
250,000
– –
LRMR icon
29
Larimar Therapeutics
LRMR
$416M
$2.4M 0.39%
+750,000
New +$1.88M
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
$1.21M 0.2%
+205,870
New +$765K
IVA
31
Inventiva
IVA
$1.05B
– –
-175,500
Closed -$995K
TNYA icon
32
Tenaya Therapeutics
TNYA
$168M
– –
-357,699
Closed -$2.01M
VTGN icon
33
VistaGen Therapeutics
VTGN
$9.29M
– –
-434,969
Closed -$11.5M
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,409,961
Closed -$23.2M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Commodore Capital held 34 positions worth $622M, up 31% from $473M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Commodore Capital deployed $50.8M of net new capital in Q3 2022, opening 10 new positions and adding to 3 existing holdings. Its largest new stake was Third Harmonic Bio: 1,018,569 shares worth $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $14.3M trimmed.

  • Commodore Capital's largest Q3 2022 buy was Third Harmonic Bio: 1,018,569 shares worth $19.3M.
  • Commodore Capital added most to Viridian Therapeutics in Q3 2022, an estimated $19M increase.
  • Commodore Capital's biggest Q3 2022 reduction was Kura Oncology, cutting an estimated $14.3M.
  • Commodore Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2022, selling an estimated $23.2M.
  • Commodore Capital's ten largest holdings make up 70% of its $622M portfolio in Q3 2022.
  • Commodore Capital opened 10 new positions and closed 4 in Q3 2022.
  • Commodore Capital's portfolio value rose 31% quarter-over-quarter to $622M.

Based on Commodore Capital's 13F filing for Q3 2022, filed 14 Nov 2022.